AI-driven biotech startup Cradle has lately secured $73 million in a Series B funding round and with this its total funding has now crossed $100 million mark. The move is significant and a step forward in the mission to reshape biotech space with artificial intelligence.

Cradle was founded by former Google engineers Stef van Grieken and Daniel Danciu in 2021. It is set to become a leader in protein engineering, a crucial area from food production to drug development and everything. The AI-powered platform helps in designing proteins and allows for faster, cheaper as well as more efficient R&D.

Research and development can take years and cost millions of dollars in the world of biotech. Cradle offers potential to speed up the process by as much as 12 times. Imagine reducing the time it takes to develop life-changing therapeutics or create animal-free foods from years to months. The Cradle platform could have good impact on industries like pharmaceuticals, food, agriculture and beyond.

The company is already attracting major partners such as Novo Nordisk, Johnson & Johnson and Ginkgo Bioworks. The companies are using its AI tools to push forward research in fields like drug discovery, food innovation and sustainable chemicals. The speed and cost savings enabled by Cradle’s platform could help bring new, life-saving products to market faster and at a fraction of the cost.

Scaling up these solutions requires money, trust, collaboration and ability to empower other scientists to use the tools. Cradle aims is to put its AI software in the hands of one million scientists. It is true that AI can revolutionize biotech as well as the way we address health and environmental issues with the right platform and the right partnerships.